丹栀逍遥丸合并喹硫平治疗双相情感障碍的临床观察  

Clinical observation of Danzhi Xiaoyao Pill combined with Quetiapine on bipolar disorder

作　　者：朱立毛 赵文旭 汪贞 黄美英 廖淑芳 徐琼 ZHU Limao;ZHAO Wenxu;WANG Zhen;HUANG Meiying;LIAO Shufang;XU Qiong(Department of Psychiatry,Shangrao Third People's Hospital,Jiangxi Province,Shangrao334000,China)

机构地区：[1]江西省上饶市第三人民医院精神科,江西上饶334000

出　　处：《中国当代医药》2024年第31期37-40,45,共5页China Modern Medicine

基　　金：江西省中医药管理局科技计划项目(2022A310)。

摘　　要：目的观察分析丹栀逍遥丸合并喹硫平治疗双相抑郁的临床疗效及不良反应。方法选取2022年6月10日至2023年12月31日上饶市第三人民医院收治的80例双相情感障碍抑郁相患者作为研究对象,采用随机数字表法分为对照组和试验组,每组各40例。对照组采用喹硫平,试验组在对照组基础上采用丹栀逍遥丸治疗。比较两组治疗前后的汉密尔顿抑郁量表-17(HAMD-17)、躁狂量表(BRMS)、副反应量表(TESS)评分及不良反应总发生率。结果试验组的治疗有效率高于对照组,差异有统计学意义(P<0.05)。治疗后第4、6、8周试验组的HAMD-17评分均低于对照组,差异有统计学意义(P<0.05)。两组BRMS评分时间、组间、两组交互比较,差异无统计学意义(P>0.05)。试验组在治疗后的第4、6、8周TESS评分均低于对照组,差异有统计学意义(P<0.05);两组的不良反应总发生率比较,差异无统计学意义(P>0.05)。结论丹栀逍遥丸与喹硫平同治双相抑郁,疗效显著;较单独采用喹硫平可进一步改善临床症状,而且不增加药物的不良反应,安全性更高,值得提倡。Objective To observe and analyze the clinical efficacy and adverse reaction of Danzhi Xiaoyao Pill combined with Quetiapine in the treatment of bipolar depression.Methods A total of 80 patients with bipolar disorder and depression treated in Shangrao Third People's Hospital from June 10,2022 to December 31,2023 were selected as the study objects,and were divided into control group and experimental group by random number table method,with 40 cases in each group.The control group was treated with Quetiapine,and the experimental group was treated with Danzhi Xiaoyao Pill on the basis of the control group.The scores of Hamilton depression scale 17(HAMD-17),Bech-Rafaelsdn mania rating scale(BRMS),treament emergent symptoms scale(TESS)and the total incidence of adverse reactions were compared between the two groups after treatment.Results The treatment effective rate of experimental group was higher than that of control group,the difference was statistically significant(P<0.05).The HAMD-17 scores of experimental groups were lower than those of control group at 4,6 and 8 weeks after treatment,with statistical significances(P<0.05).There was no significant difference in BRMS score time,between groups and interaction between the two groups(P>0.05).At 4,6 and 8 weeks after treatment,TESS scores of experimental groups were lower than those of control group,with statistical significances(P<0.05).There was no significant difference in the total incidence of adverse reactions between the two groups(P>0.05).Conclusion Danzhi Xiaoyao Pill and Quetiapine treat bipolar depression,with significant efficacy;Quetiapine alone can further improve clinical symptoms without increasing adverse effects,with higher safety.

关 键 词：丹栀逍遥丸 喹硫平 双相抑郁 临床疗效 

分 类 号：R749[医药卫生—神经病学与精神病学]